EDP-323

N/A

Report date: 2023/12/15 20:04:44
NME

Base Information

Drug NameEDP-323
Drug Alias NameEDP323EDP-323
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRNA-directed RNA polymerase L inhibitors
TargetsRNA-directed RNA polymerase L
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEnanta Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesEnanta Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsDrug-Related Side Effects and Adverse ReactionsRespiratory Syncytial Virus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A